For the quarter ending 2026-03-31, RGEN had $18,619K increase in cash & cash equivalents over the period. $23,585K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 194,255 | 197,913 | 540,343 | - |
| Cost of goods sold | 86,432 | 94,082 | 257,929 | - |
| Research and development | 14,756 | 13,120 | 41,057 | - |
| Sales and marketing | 28,214 | 27,825 | 77,495 | - |
| General and administrative | 48,913 | 45,018 | 126,563 | - |
| Total costs and operating expenses | 178,315 | 180,045 | 503,044 | - |
| Other (expense) income, net | -14,168 | 1,245 | 5,971 | - |
| Income tax (benefit) provision | -6,561 | 5,826 | 7,663 | - |
| Net income | 8,333 | 13,287 | 14,911 | 20,696 |
| Depreciation and amortization | 19,762 | 19,951 | 20,009 | 38,785 |
| Amortization of debt discount and issuance costs | 4,372 | 4,286 | 12,360 | - |
| Inventory step-up amortization | - | 491 | 1,069 | - |
| Loss on sale of business | -13,763 | - | - | - |
| Stock-based compensation | 8,322 | 7,984 | 8,973 | 15,648 |
| Deferred income taxes, net | -7,700 | 2,411 | -3,215 | -2,569 |
| Change in fair value of contingent consideration | -146 | -1,520 | -4,148 | -7,939 |
| Non-cash interest income | - | 0 | - | - |
| Loss on disposal of fixed assets | - | - | - | -3,382 |
| Loss on extinguishment of debt | - | 0 | - | - |
| Net unrealized foreign exchange loss (gain) | -38 | 571 | 190 | 12,253 |
| Unrealized loss on derivative contracts | - | - | - | -8,709 |
| Operating lease right of use asset amortization | 4,775 | 4,641 | 13,570 | - |
| Other adjustments and non-cash items | 1,327 | 902 | -2,179 | -353 |
| Accounts receivable | -3,186 | 9,863 | -7,856 | 15,158 |
| Inventories | 12,069 | 9,601 | 4,522 | 824 |
| Prepaid expenses and other current assets | 1,978 | 2,262 | 5,318 | 176 |
| Other noncurrent assets | -26 | -167 | 180 | 1,547 |
| Accounts payable | 5,918 | 933 | 3,194 | -8,277 |
| Accrued liabilities | -12,655 | 2,184 | 12,624 | -2,995 |
| Amortization of debt discount and issuance costs | - | - | - | 8,158 |
| Operating lease liabilities | -5,594 | -3,460 | -2,292 | -9,804 |
| Operating lease right of use asset amortization | - | - | - | -9,169 |
| Noncurrent liabilities | 1,269 | -2,452 | 637 | 256 |
| Total cash provided by operating activities | 28,295 | 25,704 | 48,099 | 43,614 |
| Acquisitions, net of cash acquired | 0 | 374 | 0 | 69,954 |
| Purchases of marketable securities | 64,625 | 200,257 | - | - |
| Maturities of marketable securities | 66,000 | 0 | - | - |
| Additions to capitalized software costs | 237 | 156 | 684 | 1,371 |
| Purchases of property, plant and equipment | 4,710 | 8,153 | 4,702 | 10,664 |
| Sale of property, plant and equipment | 0 | 196 | 0 | 42 |
| Purchase of intellectual property | - | 0 | - | - |
| Other investing activities | 416 | 0 | 2,397 | - |
| Total cash used in investing activities | -3,988 | -208,744 | -7,783 | -81,947 |
| Repurchase of common stock | - | 0 | - | - |
| Proceeds from issuance of 2023 notes | - | 0 | - | - |
| Repayment of 2019 notes | - | 0 | 0 | - |
| Proceeds from exercise of stock options | 0 | 1,034 | 678 | 1,464 |
| Payment of earnout consideration | - | 0 | 93 | 9,455 |
| Other financing activities | - | 0 | - | 0 |
| Payment of debt issuance costs | - | 0 | - | - |
| Payment of tax withholding obligation on vesting of restricted stock | 5,543 | 839 | 824 | 7,170 |
| Total cash used in financing activities | -5,543 | 195 | -239 | -15,161 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -145 | 119 | -185 | 4,994 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 18,619 | -182,726 | 39,892 | -48,500 |
| Cash, cash equivalents and restricted cash, beginning of period | 566,021 | 748,747 | 757,355 | - |
| Cash, cash equivalents and restricted cash, end of period | 584,640 | 566,021 | 748,747 | - |
REPLIGEN CORP (RGEN)
REPLIGEN CORP (RGEN)